文献速递慢性肾脏病

社区药师培训与沟通网络对CKD患者药物相关问题的影响:多中心集群随机对照试验

Community Pharmacist Training-and-Communication Network and Drug-Related Problems in Patients With CKD: A Multicenter, Cluster-Randomized, Controlled Trial.
PubMed 文献 · Am J Kidney Dis · 2017-06-26

该多中心集群随机对照试验在加拿大魁北克6个CKD门诊纳入442例CKD 3a-4期患者及其社区药师,评估ProFiL培训与沟通网络项目。干预组药师接受90分钟在线培训并获得临床指南、患者摘要及CKD门诊支持。1年后干预组患者人均药物相关问题减少0.32个(95%CI -0.63至-0.01),药师知识与临床能力显著提升,但临床指标无显著差异。

要点

  • 社区药师培训与沟通网络可减少CKD患者药物相关问题。
  • 干预组药师知识与临床能力较对照组显著提高。
  • 患者血压、糖化血红蛋白等临床指标未见显著组间差异。

核心结论

  • 为社区药师提供必要临床数据、适当培训及肾内科医院药师支持,可提高药师知识并减少CKD患者药物相关问题。

研究设计与样本

  • 多中心集群随机对照试验,纳入加拿大魁北克6个CKD门诊的CKD 3a、3b或4期患者及其社区药房。
  • 共207家社区药房、494名药师和442例CKD患者参与。

主要发现

  • 1年后ProFiL组患者人均药物相关问题从2.16降至1.60,对照组从1.70降至1.62。
  • ProFiL组与对照组人均药物相关问题减少的差值为-0.32(95%CI -0.63至-0.01)。
  • ProFiL组药师知识改善差值4.5%(95%CI 1.6%-7.4%),临床能力改善差值7.4%(95%CI 3.5%-11.3%)。
  • 两组临床指标(如血压、糖化血红蛋白)未见显著差异。

临床怎么用

  • 可考虑为社区药师提供CKD用药在线培训、临床指南及肾内科团队支持以优化药物管理。

局限性

  • 知识和临床技能问卷缺失数据比例较高(34.6%),临床指标缺失数据为11.1%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Appropriate training for community pharmacists may improve the quality of medication use. Few studies have reported the impact of such programs on medication management for patients with chronic kidney disease (CKD). STUDY DESIGN: Multicenter, cluster-randomized, controlled trial. SETTING & PARTICIPANTS: Patients with CKD stage 3a, 3b, or 4 from 6 CKD clinics (Quebec, Canada) and their community pharmacies. INTERVENTION: Each cluster (a pharmacy and its patients) was randomly assigned to either ProFiL, a training-and-communication network program, or the control group. ProFiL pharmacists completed a 90-minute interactive web-based training program on use of medications in CKD and received a clinical guide, patients' clinical summaries, and facilitated access to the CKD clinic. OUTCOMES: Drug-related problems (primary outcome), pharmacists' knowledge and clinical skills, and patients' clinical attributes (eg, blood pressure and glycated hemoglobin concentration). MEASUREMENTS: Drug-related problems were evaluated the year before and after the recruitment of patients using a validated set of significant drug-related problems, the Pharmacotherapy Assessment in Chronic Renal Disease (PAIR) criteria. Pharmacists' questionnaires were completed at baseline and after 1 year. Clinical attributes were documented at baseline and after 1 year using available information in medical charts. RESULTS: 207 community pharmacies, 494 pharmacists, and 442 patients with CKD participated. After 1 year, the mean number of drug-related problems per patient decreased from 2.16 to 1.60 and from 1.70 to 1.62 in the ProFiL and control groups, respectively. The difference in reduction of drug-related problems per patient between the ProFiL and control groups was -0.32 (95% CI, -0.63 to -0.01). Improvements in knowledge (difference, 4.5%; 95% CI, 1.6%-7.4%) and clinical competencies (difference, 7.4%; 95% CI, 3.5%-11.3%) were observed among ProFiL pharmacists. No significant differences in clinical attributes were observed across the groups. LIMITATIONS: High proportion of missing data on knowledge and clinical skills questionnaire (34.6%) and clinical attributes (11.1%). CONCLUSIONS: Providing community pharmacists with essential clinical data, appropriate training, and support from hospital pharmacists with expertise in nephrology increases pharmacists' knowledge and reduces drug-related problems in patients with CKD who are followed up in clinics incorporating a multidisciplinary health care team.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Lalonde L, Quintana-Bárcena P, Lord A, et al. Community Pharmacist Training-and-Communication Network and Drug-Related Problems in Patients With CKD: A Multicenter, Cluster-Randomized, Controlled Trial. Am J Kidney Dis. 2017. PMID: 28663062. doi:10.1053/j.ajkd.2017.05.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。